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Abstract
Background: Foot ulceration is the main precursor to lower limb amputation in patients with type 2 diabetes
worldwide. Biomechanical factors have been implicated in the development of foot ulceration; however the
association of these factors to ulcer healing remains less clear. It may be hypothesised that abnormalities in
temporal spatial parameters (stride to stride measurements), kinematics (joint movements), kinetics (forces on the
lower limb) and plantar pressures (pressure placed on the foot during walking) contribute to foot ulcer healing. The
primary aim of this study is to establish the biomechanical characteristics (temporal spatial parameters, kinematics,
kinetics and plantar pressures) of patients with plantar neuropathic foot ulcers compared to controls without a
history of foot ulcers. The secondary aim is to assess the same biomechanical characteristics in patients with foot
ulcers and controls over-time to assess whether these characteristics remain the same or change throughout ulcer
healing.
Methods/Design: The design is a case–control study nested in a six-month longitudinal study. Cases will be
participants with active plantar neuropathic foot ulcers (DFU group). Controls will consist of patients with type 2
diabetes (DMC group) and healthy participants (HC group) with no history of foot ulceration. Standardised gait and
plantar pressure protocols will be used to collect biomechanical data at baseline, three and six months. Descriptive
variables and primary and secondary outcome variables will be compared between the three groups at baseline
and follow-up.
Discussion: It is anticipated that the findings from this longitudinal study will provide important information
regarding the biomechanical characteristic of type 2 diabetes patients with neuropathic foot ulcers. We hypothesise
that people with foot ulcers will demonstrate a significantly compromised gait pattern (reduced temporal spatial
parameters, kinematics and kinetics) at base line and then throughout the follow-up period compared to controls.
The study may provide evidence for the design of gait-retraining, neuro-muscular conditioning and other
approaches to off-load the limbs of those with foot ulcers in order to reduce the mechanical loading on the foot
during gait and promote ulcer healing.
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Background
Foot ulceration is the main precursor to lower limb am-
putation in patients with diabetes worldwide [1]. Esti-
mates of the prevalence of diabetic foot ulcers (DFUs) in
the United States range between 4 and 12 % [1]. The an-
nual and lifetime incidence of DFUs has been estimated
as approximately 4 and 25 %, respectively [1]. In
Queensland, Australia, 24,917 hospital admissions were
used for the principal management of a diabetes related
foot complication between 2005 and 2010 resulting in
the use of 260,085 hospital occupied bed days [2]. Treat-
ment of DFUs account for significant health care costs
in Australia and foot complications are the second leading
cause of diabetes related mortality, second only to cardio-
vascular disease [3]. Most foot ulcers are triggered by dia-
betes associated peripheral neuropathy (DPN) [4, 5]. DPN
which is believed to be a consequence of uncontrolled
hyperglycaemia, prompts gradual loss of sensory, motor
and autonomic function of the lower limb which leads to
foot deformities, abnormal gait and higher plantar
pressures which promote skin trauma and subsequent
DFUs [4, 6–8].
Although biomechanical studies have helped to iden-
tify potential triggers of ulceration, whether such triggers
change and by how much when DFUs are healing re-
mains largely unknown [9, 10]. It is unknown whether
patients with DPN are capable of adjusting their gait and
plantar pressure (i.e. reducing pressure) to account for
plantar wounds, as is the case for healthy controls with
normal peripheral sensation [9]. It can be hypothesised
that due to DPN, patients with active plantar DFUs
would continue to demonstrate similar abnormal lower
limb biomechanical characteristics as displayed prior to
the DFU formation [10]. Biomechanical factors associ-
ated with DFUs include reduced temporal spatial param-
eters (TSPs), such as speed of walking and stride length;
restricted kinematics (movement patterns); delayed
muscle activations; and altered forces (kinetics),which
may contribute to elevated plantar pressures during gait
[9]. It may be possible that the patients who achieve suc-
cessful DFU healing are able to compensate for the DFU
through changes to these biomechanical factors, irre-
spective of external devices used to offload ulcers. Find-
ings from a recent meta-analysis suggested that patients
with active DFUs have reduced plantar pressure com-
pared to those with DPN without ulcers, contrary to
what was previously thought [9]. We proposed that a
‘guarded gait strategy’ may be adopted by patients with
active DFUs to potentially achieve successful DFU heal-
ing leading to reduced plantar pressure [9]. To our
knowledge, this concept has not previously been investi-
gated. It is likely that exploring the gait and plantar pres-
sure of patients with DFUs during barefoot walking
(without the influence of off-loading devices or shoes)
over-time will advance knowledge of how gait changes
during DFU healing.
Detailed information about the biomechanical factors
in patients with active DFUs may provide evidence for
the design of gait-retraining and neuro-muscular condi-
tioning and more efficient offloading methods to reduce
the mechanical loading on the foot during gait [10–12].
Findings may also provide a means to select the most
appropriate patients for different off-loading methods to
improve DFU healing. The primary aim of this study is
to establish the lower limb biomechanical characteristics
(TSPs, kinematics, kinetics, muscle activations and plan-
tar pressures) of patients with plantar neuropathic DFUs.
The secondary aim is to assess the changes in these
characteristics at 3 months and 6 months follow-up.
This protocol details the proposed methodology for this
planned study.
Methods/Design
Study design and participants
A case–control study nested in a six month longitudinal
study was planned. The study will be performed in
Townsville, a regional town in north Queensland,
Australia with an approximate population of 175,000
and an estimated type 2 diabetes prevalence of 4.4 % [13].
Type 2 diabetes patients with active unilateral plantar
DFUs (DFU group), type 2 diabetes control patients with-
out a history of DFUs (DMC group) and healthy controls
without diabetes or DFUs (HC group) will be recruited for
this study. We will attempt to match the sex of both
control groups with that of cases and match age within a
range of 5 years. A 1:4:2 ratio of cases to controls [DFU:
DMC: HC] is planned due to the expected difficulty in
recruiting DFU patients in comparison to controls.
Figure 1 outlines the proposed study protocol. All as-
sessments will be carried out by the principal investiga-
tor (MEF), who is a trained podiatrist undertaking a
PhD.
Definitions of outcome measures and families of
biomechanical outcomes
The primary and secondary outcome measures of the case
control and longitudinal studies include several biomechan-
ical variables. These variables will be grouped into gait and
plantar pressure outcomes and will contribute to four main
families of hypotheses. The four families of biomechanical
hypotheses are 1) abnormal TSPs, such as speed of walking
and stride length; 2) restricted kinematics (movement pat-
terns); 3) altered kinetics, (altered forces) and 4) elevated
plantar pressures on the ulcerated and non-ulcerated foot
[9]. The kinematics can be further divided into three fam-
ilies; 5) sagittal plane kinematics, 6) frontal plane kinematics
and 7) transverse plane kinematics. Therefore there are
seven families of hypotheses in total. The main hypothesis
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is that patients with active plantar DFUs have altered
lower limb biomechanical characteristics compared to
healthy and diabetes controls. The follow-up hypothesis
is that the biomechanical characteristics of patients with
DFUs will not significantly change over six months
follow-up compared to the DMC group.
Primary outcome measures relating to plantar pressure
will include the:
 Mean peak pressure: The mean peak pressure
(average peak pressure), in N/cm2 recorded
within the plantar aspect of foot at ten anatomical
sites;
 Maximum peak pressure: The maximum peak
pressure in N/cm2 recorded within the plantar
aspect of foot at ten anatomical sites;
 Total contact area of the foot: The area of the
plantar aspect of the foot in contact with the
pressure platform in cm2 at ten anatomical sites;
 Estimated vertical ground reaction force: The
contact area multiplied by the mean peak plantar
pressure in Newtons (N) at ten anatomical sites.
Primary outcome measures relating to gait will
include:
 TSPs (walking speed, cadence, stride time, step time,
opposite foot off time, opposite foot contact, foot off
time, single support time, double support time,
stride length and step length);
 Kinematic variables (angular joint movement
characteristics of the pelvis, hip, knee and ankle
bilaterally in the sagittal, transverse and frontal
planes during the gait cycle);
 Kinetic variables (forces): Reported as the vertical,
medial-lateral and anterior-posterior components
of ground reaction force during the gait cycle in
Newtons (N);
Secondary outcome measures for gait will include:
 Muscle voltages for six lower limb muscles including
the vastus medialis, peroneus longus, tibialis
anterior, semitendinosus and medial and lateral
gastrocnemius during the gait cycle;
Fig. 1 Outline of the study. Legend: DFU group = type 2 diabetes mellitus patients with a unilateral plantar foot ulcer, DMC group = patients with
type 2 diabetes mellitus without a history of foot ulcers, HC group = healthy controls without type 2 diabetes mellitus or a history of foot ulcers
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 Joint accelerations and velocities, in the sagittal,
transverse and frontal planes during the gait cycle,
reported as degrees per second (°/s) and degrees per
second squared (°/s2).
 Joint powers during gait: Reported as the estimated
power generated by the muscles acting at the hip,
knee and ankle during gait, in Watts (W);
 Joint moments generated at the hip, knee and ankle
bilaterally in the sagittal, transverse and frontal
planes during the gait cycle, reported in Newton
meters (Nm).
Sample size calculations
We plan to examine multiple hypotheses in this study.
Sample sizes were calculated to test the hypothesis that
forefoot plantar pressures were different in patients with
active DFUs compared with controls. This hypothesis
was chosen for the sample size calculation since previ-
ous studies suggested this measure had large between
patient variability and therefore was likely to require the
largest sample size [14]. The effect size for this calcula-
tion was based on previous research where higher plan-
tar pressures were documented in patients with DPN
without a DFU history compared to healthy controls
without either DPN or DFUs [15]. The sample size was
based on an expected mean (standard deviation) forefoot
plantar pressure of 3.2 (1.0) N/cm2; 3.9 (1.0) N/cm2; and
4.7 (2.0) N/cm2 for the HC, DMC and DFU groups, re-
spectively. It was estimated that those with DFUs would
have at least a 20 % higher plantar pressure than the
control groups due to the observed difference in means
of those with DPN and healthy controls [15]. We also
accounted for the potential difficulty in recruiting active
DFU cases in our sample size calculations by inflating
the control to case ratio. Therefore, a ratio of 1 DFU; 4
DMC; 2 HC was used. We estimated that 28, 112 and 56
participants were required in the DFU, the DMC and
the HC groups, respectively, using a one-way analysis of
variance (ANOVA) with 80 % power and an overall sig-
nificance of 0.05 (maximum of 8 planned hypotheses to
be tested). The planned hypotheses to be tested are:
 The DFU group will demonstrate significantly
poorer TSPs compared to controls at baseline.
 The DFU group will demonstrate significantly
restricted kinematics at the ankle, knee, hip and
pelvis compared to controls at baseline.
 The DFU group will demonstrate significantly
altered kinetics (anterior posterior, medial-lateral
and vertical ground reaction forces) compared to
controls at baseline
 The DFU group will demonstrate significantly
different plantar pressure. characteristics (mean
peak, maximum peak, contact area and localised
vertical ground reaction forces) compared to
controls at baseline.
 The TSPs in the DFU group will remain poorer at
3 and 6 months follow-up compared to the DMC
group.
 The kinematics of the DFU group will remain
different at 3 and 6 months follow-up compared to
the DMC group.
 The kinetics of the DFU group will remain different
at 3 and 6 months follow-up compared to the DMC
group.
 The plantar pressure characteristics of the DFU
group will remain different at 3 and 6 months
follow-up compared to the DMC group.
Due to the large number of hypotheses, we planned to
correct for multiple testing which is described in detail
in the statistical analyses section. We inflated the sample
sizes to account for a proposed 10 % drop-out rate dur-
ing the six month follow-up and therefore 31, 123 and
58 participants were required in the DFU, the DMC and
the HC groups, respectively. An interim analysis of the
study is planned after recruiting 50 % of the estimated
number of participants for each group. This is to re-
assess the proposed sample sizes since the initial effect
size was based on patients that had DPN but no DFUs.
A post-hoc power test will be performed to re-assess ac-
tual statistical power when recruitment is concluded.
This test will be focused on plantar pressure values mea-
sured in the forefoot. All sample sizes were performed
using the G*Power statistical software (G* Power version
3.1, Faul, Erdfelder, Lang, & Buchner, Germany) [16].
Sample selection and setting
The DFU and DMC patients will be recruited from in-
patient wards, outpatient clinics and community health
clinics within the Townsville Hospital and Health
Service District, Queensland, Australia. The HC group
will be recruited through community advertising and
from staff at the university where the study will take
place. The study is approved by The Townsville Hospital
and Health Service District and the James Cook University
human research ethics committees (approval numbers
HREC/12/QTHS/77 and H4693). Written informed con-
sent will be obtained from all participants at the time of
screening for participation in the study and for publication
of de-identified data.
Inclusion criteria
Inclusion criteria for the cases (DFU group) include:
males and females above the age of 18 years; a diagnosis
of type 2 diabetes (confirmed on review of the patient’s
hospital or General Practitioner record) and a single ac-
tive unilateral plantar DFU of >3 months duration which
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is not completely epithelialized. The DMC group will
comprise males and females above the age of 18 years,
with a diagnosis of type 2 diabetes (similarly defined as
for the DFU group) and no history of plantar DFUs. The
HC group will comprise participants who do not have
either a diagnosis of type 2 diabetes or any foot ulcer
history as assessed on interview and examination.
Exclusion criteria
All participants will be required to be able to ambulate
without any assistance or mobility aids. The exclusion
criteria were designed to exclude participants with prob-
lems impacting on mobility which would likely mask the
impact of plantar DFUs on gait. Exclusion criteria for re-
cruitment to all three groups are: (1) chronic or acute
orthopaedic, musculoskeletal, vestibular, visual or neuro-
logical problems affecting mobility (other than DPN) at
the time of screening; (2) any history of orthopaedic sur-
gical intervention of the lower limb (including knee
arthroplasty, ankle reconstruction, bunionectomy and
any other orthopaedic surgical intervention of the hip,
knee or foot (besides history of surgical debridement of
tissue in the DFU group); (3) presence of any form of
diabetes other than type 2 diabetes; (4) planned vascular
reconstruction; (5) pregnancy; and (6) systemic disease
affecting mobility or leading to chronic inflammation of
any lower limb joint.
All participants will need to demonstrate visual acuity
adequate for walking. This will be assessed by asking the
participant whether they had visited an optometrist in
the last twelve months and whether they had difficulty
walking due to visual impairment. If they have not vis-
ited an optometrist, participants would be required to
do this before being considered for the study. Visual
acuity will then again be checked prior to group alloca-
tion. We do not plan on excluding participants with dia-
betic retinopathy as this is an associated microvascular
condition of diabetes, provided that participants do not
disclose limitations in their vision that affected their
walking ability. All participants unable to fulfil these cri-
teria will be excluded from the study. Peripheral artery
disease will be excluded as a major contributing cause of
foot ulceration by a number of methods. Firstly the DFU
patients will be reviewed by a board accredited vascular
specialist (JG) who will take a relevant history and per-
form clinical examinations to exclude significant periph-
eral artery disease. DFU patients will need to demonstrate
an absence of symptoms of intermittent claudication [17]
and an ankle-brachial pressure index (ABPI) of >0.8
bilaterally, for inclusion. Participants enrolled in the
control groups will also need to demonstrate an ab-
sence of symptoms of intermittent claudication [17]
and an ABPI of >0.8 bilaterally. Any participants who
demonstrate ABPIs of >1.3 will also be referred to the
vascular specialist for review of inclusion [18]. Participants
will not be excluded on grounds of a history of peripheral
vascular reconstruction provided they demonstrate ad-
equate peripheral circulation at the time of screening as
based on the criteria listed above.
Baseline measurements
Clinical history and demographic assessment
A previously developed and detailed case report form
(see Additional file 1: Supplementary file S1) will be used
for collecting data. A medical history will be obtained
from participants via a structured interview using the
case report form at baseline and follow-up visits. The
case report form will be used to collect information on:
Demographic details; history of significant medical con-
ditions and treatments; medication history; ethnicity,
particularly in relation to indigenous status [19]; diabetes
history, such as duration of diabetes and family history
of diabetes [20, 21]; smoking history [22]; walking and
exercise habits [23]; and footwear use [24]. Participants
will be interviewed by a single researcher (MEF). The
hospital or clinical charts of patients with type 2 diabetes
will also be reviewed. Medical conditions recorded will
include: Hypertension, defined as history of diagnosis or
treatment with antihypertensive medication; dyslipidae-
mia, based on history or treatment with hypolipidemic
agents; stroke, defined as a history of an ischemic or
haemorrhagic stroke; coronary heart disease, defined as
history of stable angina or unstable angina or myocardial
infarction; chronic heart failure, based on clinical history
of congestive heart failure; chronic pulmonary disease,
based on clinical history and/ or treatment; chronic liver
disease, based on clinical record; chronic kidney disease,
defined as an estimated glomerular filtration rate (eGFR)
of <60 ml/min/1.73 m2 for 3 months recorded in the
medical records. These risk factors are either known to
influence foot ulcer development or healing [25], are
considered as complications or conditions associated
with type 2 diabetes [21, 26, 27], or are related to general
health and function [28].
Blood tests
Information will also be collected regarding blood
markers that are obtained as part of clinical care of par-
ticipants with type 2 diabetes. Blood markers to be re-
corded include HbA1c, circulating lipids and eGFR
measured in a local pathology department. Ion-exchange
high-performance liquid chromatography (HPLC) will
be used to estimate HbA1c as a measure of long-term
glycaemic control with the RIANT II TURBO Link Sys-
tem (Bio-Rad Laboratories, USA) [29]. Serum lipids will
be measured by separating serum from the whole blood
and performing analysis for total cholesterol, triglycer-
ides, low-density lipoprotein (LDL), and high density
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lipoprotein (HDL) using automated assays on an Abbott
Architect ci8200 machine (Abbott Park, IL, USA) [30].
eGFR will be calculated using the Chronic Kidney Disease-
Epidemiology Collaboration group (CKD-EPI) formula,
which is validated for Australian populations [31, 32].
Anthropometric assessments
Physical examination will involve the assessment of
height, weight, body mass index (BMI), body fat percent-
age and waist and hip circumference. All clinical and an-
thropometric measures (described below) will be carried
out three times and averaged. Participant’s height will be
measured using a wall mounted telescopic metal stadi-
ometer (Seca model 220, Seca Scales, Hamburg, Germany).
Percentage body fat (% body fat) will be estimated using
bioelectrical impedance scales (TANITA TBF 521, TANITA
Corporation, Arlington heights, Illinois, USA) which also
measures weight (Kg) [33]. BMI will be calculated by divid-
ing the participant’s body mass (Kg) by the square of the
participant’s height (m). A standardised metal measuring
tape (KDSF10-02, KDS Corporation, Osaka, Japan) will be
used to assess hip and waist circumference while the par-
ticipant is in a relaxed stance positon with feet together and
arms freely hanging to the side. The measurement will be
performed at the end of exhalation [34]. Waist circumfer-
ence will be measured at the natural waist i.e. in between
the lowest rib and the top of the iliac crest at the narrowest
point of the lower abdomen [34]. Hip circumference will be
considered as the widest portion of the buttocks, with the
tape parallel to the floor [35]. Measurements will be re-
peated three times and averaged [34].
Blood pressure and peripheral arterial examination
Blood pressure (systolic and diastolic) will be measured
using an electronic blood pressure machine (Connex
ProBP 3400 digital blood pressure device; Welch Allyn,
New York, USA) mounted on a mobile stand [36]. Systolic
and diastolic measurements will be taken in both arms
while the participant is sitting and relaxed, and repeated
three times, two minutes apart [37]. The highest averaged
value from the two arms will be used to represent partici-
pant’s blood pressure. Blood pressure measurements will
be performed using an appropriately sized sphygmoman-
ometer cuff (i.e. using a large-adult cuff size for individuals
with an arm circumference of 33 cm or greater) [38].
The peripheral arterial examinations will first comprise
the palpation of the dorsalis pedis and posterior tibial
pulses for their presence or absence as well as strength
(categorised as normal or reduced) [39]. The ABPI will
be measured in each lower limb using previously vali-
dated methods [40]. The ABPI will be performed with
the participant lying on a plinth and after being rested
for ten minutes. A 5 MHz Doppler probe (MD 6,
Hokanson, Bellevue, USA) angled at 45° to the direction
of the blood flow will be used to assess the ABPI. The
brachial artery pulse will be manually palpated and the
Doppler probe will be used to detect a signal. The
sphygmomanometer cuff will be inflated until the Dop-
pler signal disappears and deflated slowly until the signal
returns. The pressure at which the signal returns will be
recorded as the brachial artery Doppler pressure. Three
brachial artery Doppler pressure measurements will be
taken in each arm using this method. The sphygmoman-
ometer cuff will then be placed around the participant’s
ankle immediately above the medial and lateral malle-
olus and the Doppler probe will be placed on the dorsa-
lis pedis artery after palpation. The above mentioned
process will be repeated three times to assess the dorsa-
lis pedis artery Doppler pressure. A similar process will
be carried out to assess the posterior tibial artery Dop-
pler pressure. The highest average Doppler pressure
measurement in each ankle will be divided by the high-
est average brachial pressure to obtain an ABPI value for
each foot. We utilised the combination of ABPI and
claudication symptom questionnaire to identify periph-
eral artery disease as previously reported [17]. This com-
bination is thought to provide a better means of
detecting peripheral artery disease, especially since
falsely elevated ABPI values are common in patients
with diabetes mellitus [18, 41].
Screening for diabetic peripheral neuropathy presence
and severity
Neurological examination will consist of a 10 g (size
5.07) monofilament sensation test [42], a 128 Hz tuning
fork sensation perception test [43] and administration of
the Michigan neuropathy screening instrument (MNSI)
(Michigan Diabetes Research and Training Center, 2013)
[44]. The MNSI is a tool which has been validated for
assessment and quantification of the degree of peripheral
sensory and motor neuropathy present in participants
with diabetes [44]. This includes asymptomatic periph-
eral neuropathy [45]. The tool contains both a symptom
and physical component [46]. A score out of 11 will be
generated for the symptom related questions of the
MNSI and a score out of eight will be generated for the
physical assessment component.
Monofilament sensation will be assessed at ten sites
(two additional sites compared to previous reports) on
each foot including the plantar surfaces of the heel on
the medial and lateral sides, hallux, apex of toes 2–5,
metatarsal one, metatarsal five and the dorsum of the
foot between the first and second metatarsals [47]. The
examination will be performed with the participant lying
supine in a relaxed position with their eyes closed. The
participant will be given the opportunity to feel the sen-
sation in their index finger prior to testing in the foot.
The monofilament will be applied for <1 s at each site
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and the participant will be requested to verbally acknow-
ledge whether they felt the sensation and to acknow-
ledge the site of sensation [48]. A score of five or less
out of eight has been reported to indicate the presence
of peripheral neuropathy based on assessing eight sites
[47]. We will utilise this grading system with the inclu-
sion of two additional sites to encompass the main re-
gions of the whole foot. Where a participant is unable to
detect the monofilament at five or less sites they will be
considered to have DPN [47]. Additionally a 128 Hz tun-
ing fork will be applied to the tip of the hallux at the
bony prominence of the distal phalanx on both feet to
check whether vibration sensation is present [43, 49].
Patients will be asked to verbally indicate the com-
mencement and cessation of vibration sensation upon
application and dampening of vibration four times on
each hallux [43]. Vibration sensation will be assessed on
a scale of 0 to 8 in each leg based on the number of
times vibration commencement and cessation is felt ac-
curately [49]. The scores obtained will be reported and
compared between groups.
Physical examination of the lower extremities
The lower limb examination will encompass an assess-
ment of the static range of movement of the ankle joints,
sub-talar joints and the first metatarsophalangeal joints
using previously described methods [50, 51]. A goniom-
eter will be used while the participant is relaxed and
lying on an examination plinth and while the patient’s
legs are in complete extension [50, 51]. Ankle and sub-
talar joint range of motion will be recorded as a categor-
ical outcome where the movement will be classified as
restricted, normal or hypermobile based on the range of
movement of the joint [52]. The muscle power of the
lower limbs will be assessed using the Medical Research
Council (MRC) scale [53] while the participant is lying
supine. The degree of movement of the foot in the sagit-
tal, coronal and frontal planes will be documented dur-
ing abduction/adduction, plantar flexion/dorsiflexion
and inversion/eversion. MRC grading will be evaluated
as a categorical value with a score less than five indicat-
ing a restriction in movement [53]. Other assessments
will include examination of the medial longitudinal arch
contour (both on stance and during sitting) [54], an
examination for lesser toe deformities (claw, hammer
and mallet toes) [55] and the identification of the pres-
ence and degree of hallux valgus (HAV) deformity of the
first metatarsophalangeal joints [11, 56].
Assessment and classification of plantar foot ulcers
The University of Texas Wound Classification System
(UTWCS) is a validated tool for the measurement of
foot ulcers [57]. The UTWCS will be used to grade the
ulcer for severity based on the presence of infection,
ischemia and depth. Photographs will be taken of each
participant’s DFU at each visit and wound measurements
will be conducted by MEF to measure depth, width and
length of the ulcer in cm and the surface area will be
calculated using the formula length (cm) x width (cm) =
surface area (cm2) [58]. Other information such as the
ulcer location, the estimated duration of the ulcer (in
weeks; recorded at the initial date of presentation within
the notes to the time of assessment), the wound exudate
level, the type of exudate, the appearance of the wound
bed (base of the wound) and wound edge, and the pres-
ence of sinus formation will also be collected [58, 59]. If
clinical signs of infection are apparent (using Infectious
Diseases Society of America Clinical Practice Guideline
for the Diagnosis and Treatment of Diabetic Foot Infec-
tions [60]) then a wound swab will be performed [61, 62]
to identify the presence of bacterial infection as a
part of treatment of the ulcer as reported in current
guidelines [62–64].
The type of offloading utilised and the type and frequency
of wound dressings will also be collected [63, 65, 66]. All
patients with DFUs will be given a standard single-layer
generic film wound dressing which they will wear over the
wound during gait examination to minimise the impact of
wound dressings on the study results and to standardise
the type of dressing during gait assessments. As a precau-
tionary measure, participants with DFUs will only be re-
quested to weight bear while gait and plantar pressure
assessments are being carried out and they will be
instructed to remain sitting with their feet off the ground as
much as possible between assessments.
Assessment of gait
The three dimensional movement analysis component of
the study will involve attaching reflective markers to the
participant’s skin over the surface of key anatomical land-
marks [67]. This enables the assessment of movement
characteristics such as TSP’s, joint kinematics, power and
moments [68]. The movement analysis laboratory at
James Cook University will be used for gait assessments.
This lab is equipped with the VICON gait analysis system
(VICON, Oxford, United Kingdom). The system has ten
T-40 series infrared cameras positioned around a walking
environment capturing data at 100 Hz within the VICON
nexus movement analysis software (version 1.9.1, VICON,
Oxford, United Kingdom). The force plates in the labora-
tory comprise of two 400 × 600 mm OR-6 AMTI force
plates and two 900 × 900 mm OR-6 AMTI force plates
(AMTI, Watertown, Massachusetts, USA) which are em-
bedded on a 10 m long walking surface covered by con-
crete overlay. The force plates have a maximum excitation
range of 10 volts with each occupying six analogue
channels (<2 % channel cross talk). In addition to
this, two Bortec AMT 8 Electromyography systems
Fernando et al. BMC Endocrine Disorders  (2015) 15:59 Page 7 of 11
(Bortec Biomedical, Alberta, Canada), comprising 16
individual channels will be utilised to capture electro-
myographic data. The force plates and electromyo-
graphic unit are programmed to capture at a rate of
3000 Hz (3000 frames per second), for optimum cap-
ture speed whilst utilising all equipment simultan-
eously. All equipment are linked and synchronized
with the VICON system in the laboratory. A similar
system was used in a recent study investigating gait
features of patients with trans-tibial amputation [69]
and in another study assessing gait in patients with a
history of foot ulcers [70].
A standard VICON Nexus procedure will be used dur-
ing motion capture (Vicon Motion Systems, Oxford,
England) [71]. Ten walking assessments while walking at
a self-selected pace will be collected from each partici-
pant. These ten walking assessments will be averaged
and compared across groups.
Assessment of plantar pressure
The Footscan® pressure plate (RSScan International,
Olen, Belgium) will be used for plantar pressure as-
sessment with the associated Foot Scan® processing
software. This platform is two meters in length, 0.4 m
in width and contains 16,384 sensors capturing at
100 Hz. The plantar pressure platform is freestanding.
The platform has been used for previous biomechan-
ical research in participants that have diabetes [72].
Ten walking assesments will be collected from partic-
ipants while walking at a self-selected pace using the
three step-protocol [73]. This involves the participant
being trained to approach the plantar pressure plat-
form so as to strike their third step (i.e. contact of
the initiating limb) on the pressure platform first
followed by the opposite foot second [73]. The pres-
sure measurement software permits masking of the
foot to enable identification of plantar pressures at a
total of 20 anatomical locations in both feet. This al-
lows for the quantification of plantar pressure based
on pre-established anatomical locations [7]. The loca-
tions include the plantar surfaces of the hallux, com-
bined toes one to five, metatarsal one, metatarsal two,
metatarsal three, metatarsal four, metatarsal five, the
mid foot, the lateral rear foot and the medial rear
foot. These measurements are reported by the soft-
ware as the mean peak pressure (mpp), maximum
sensor pressure (msp), pressure time integral (pti) and
contact area (ca). A consistent measurement will be
defined as a walking assessment in which all ten ana-
tomical locations were visible with a numerical value
for mpp, msp, pti and ca in both feet and where lat-
eral or medial deviation of the foot off the pressure
platform did not occur [7].
Measurements to be repeated at the follow-up
assessments
Follow-up assessments will be performed on all partici-
pants in the DFU and DMC groups at three and six
months. The HC group will be only examined at baseline
as it is anticipated that the gait and plantar pressure of
these participants will not change during short term
follow-up [74]. The case report form (see Additional file 1:
Supplementary file S1) will be used for collecting data
at each follow-up visit. Follow-up assessment will in-
volve a physical examination, including assessment of
height, weight, BMI, % body fat and waist and hip
circumference. A questionnaire contained within the
case report form will be used to assess any changes
to participants’ medical history or medication. This
form will also be used to document foot ulcer recurrence,
new ulcer formation and ulcer healing, new treatments
and foot ulcer characteristics (if applicable). Gait and plan-
tar pressure measurements will be performed at the three
and six months follow-up visits to assess any changes to
the primary and secondary outcome measures. Eligibility
to participate will be reassessed at each visit and any rea-
sons for discontinuation of the study will be recorded and
reported.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS)
version 22.0 for Windows (SPSS Inc., Chicago, IL, USA)
will be used for statistical analyses. Continuous data will
be reported as mean ± standard deviation or median and
interquartile range based on the distribution of data in
the three groups. The Shapiro-Wilk test will be used to
test for normality. All primary and secondary outcome
variables will first be assessed graphically using scatter
and box plots and using correlation analyses to look at
between group differences in data. If the data is of nor-
mal distribution, parametric analyses will be used. Ex-
planatory variables will be compared between the groups
using one way ANOVA and between the DFU and DMC
groups using student t-test for continuous variables.
Non-parametric analyses with the Kruskal Wallis test
and the Man Whitney U test will be used if the data is
not normally distributed. Pearson’s chi-square tests or
Fisher’s exact tests will be used for categorical variables.
Fisher’s exact test will be used where the expected fre-
quencies are less than or equal to five. Similarly, primary
and secondary continuous data outcomes will be initially
analysed using one way ANOVA or Kruskal Wallis test
based on distribution of the data. Outcomes will be cor-
rected for multiple testing where more than the planned
number of hypotheses are tested and where more than
the planned four families of hypotheses are tested. The
Holm correction will be used for correcting p-values of
unplanned tests [75]. This will correct for type 1 error.
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Type 2 errors are controlled by using sample size calcu-
lations. P-values from the test statistic and 95 % confi-
dence intervals of the mean will be reported for each
group for each outcome measure as a measure of signifi-
cance. Effect-sizes of each significant outcome measure
will be reported using the Cohen D value in reference to
previously reported biomechanical effect sizes [76].
Where possible and appropriate, analyses using binary
logistic regression will be performed to adjust for potential
confounding including age, gender and BMI, despite
matching, for all significant outcomes. Follow-up data will
be analysed using either repeated measures ANOVA or a
similar repeated measures analysis of variance statistical
technique such as generalised linear mixed models, utilis-
ing time as a co-variate to assess changes in gait and plan-
tar pressure variables over-time. Alpha will be set to 0.05
for all analyses.
Discussion
We report the methodology for a longitudinal study in-
vestigating the gait and plantar pressure characteristics
of patients with active DFUs. There is a paucity of stud-
ies investigating the biomechanical characteristics of pa-
tients with active neuropathic DFUs and thus a need to
better document these characteristics. Altered biomech-
anical characteristics are likely to influence the healing
of plantar DFUs. It may be possible to address altered
biomechanical characteristics to reduce the mechanical
loading on the ulcerated foot during gait using gait
retraining techniques in addition to off-loading the foot.
The design of these interventions is likely to be im-
proved by further understanding of gait during the pres-
ence of an ulcer. We believe this study will provide
important observations regarding the association be-
tween gait and foot ulcer healing.
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containing the case report form for data collection. (PDF 1054 kb)
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